EPAS1 and hepatocellular carcinoma: Notably, a Phase I/II clinical trial (NCT04976634) is assessing the safety and efficacy of Belzutifan (MK-6482), a selective HIF-2α inhibitor [46], in combination with Lenvatinib, a tyrosine kinase inhibitor, for patients with advanced HCC.